169 related articles for article (PubMed ID: 11381289)
1. Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?
Mancini GB; Stewart DJ
Can J Cardiol; 2001 May; 17 Suppl A():15A-7A. PubMed ID: 11381289
[TBL] [Abstract][Full Text] [Related]
2. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
3. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
4. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
5. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
[TBL] [Abstract][Full Text] [Related]
6. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
7. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
McQueen MJ; Lonn E; Gerstein HC; Bosch J; Yusuf S
Scand J Clin Lab Invest Suppl; 2005; 240():143-56. PubMed ID: 16112972
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
9. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
[TBL] [Abstract][Full Text] [Related]
10. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.
Lancet; 2000 Jan; 355(9200):253-9. PubMed ID: 10675071
[TBL] [Abstract][Full Text] [Related]
11. Future perspectives and implications.
Sleight P
Int J Clin Pract Suppl; 2001 Jan; (117):22-3. PubMed ID: 11715355
[TBL] [Abstract][Full Text] [Related]
12. [Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
Pocanić D
Lijec Vjesn; 2011; 133(1-2):69-71. PubMed ID: 21644282
[TBL] [Abstract][Full Text] [Related]
13. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510
[TBL] [Abstract][Full Text] [Related]
14. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.
Blankenberg S; McQueen MJ; Smieja M; Pogue J; Balion C; Lonn E; Rupprecht HJ; Bickel C; Tiret L; Cambien F; Gerstein H; Münzel T; Yusuf S;
Circulation; 2006 Jul; 114(3):201-8. PubMed ID: 16831981
[TBL] [Abstract][Full Text] [Related]
15. [The HOPE Study. What does it contribute to general practice?].
Mann J; Sleight P
MMW Fortschr Med; 2000 Nov; 142(47):28-32. PubMed ID: 11143776
[TBL] [Abstract][Full Text] [Related]
16. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
17. Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.
Gianni M; Bosch J; Pogue J; Probstfield J; Dagenais G; Yusuf S; Lonn E
Eur Heart J; 2007 Jun; 28(11):1382-8. PubMed ID: 17395677
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?
Boos CJ
Med Sci Monit; 2004 Dec; 10(12):SR23-8. PubMed ID: 15567997
[TBL] [Abstract][Full Text] [Related]
19. [How should ACE inhibitors be used in myocardial infarction?].
Reikvam A; Madsen S
Tidsskr Nor Laegeforen; 2000 Nov; 120(28):3413-7. PubMed ID: 11187196
[TBL] [Abstract][Full Text] [Related]
20. Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).
Kjøller-Hansen L; Steffensen R; Grande P
Am Heart J; 2004 Sep; 148(3):475-80. PubMed ID: 15389235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
